Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Apr;3(3):257-74.
doi: 10.1186/1479-7364-3-3-257.

Pharmacogenetics of antidepressant response: an update

Antonio Drago  1 , Diana De Ronchi, Alessandro Serretti
Affiliations
Review

Pharmacogenetics of antidepressant response: an update

Antonio Drago et al. Hum Genomics. 2009 Apr.

Abstract

The past few decades have witnessed much progress in the field of pharmacogenetics. The identification of the genetic background that regulates the antidepressant response has benefited from these advances. This review focuses on the pharmacogenetics of the antidepressant response through the analysis and discussion of the most compelling evidence in this line of research. Online databases (Medline and PsycINFO) have been searched and the most replicated association findings relating to the genetics of the antidepressant response have been reported and discussed. Some replicated findings in the literature have suggested the serotonin transporter promoter (5-HTTLPR), serotonin receptor 1A (HTR1A), serotonin receptor 2A (HTR2A), brain derived neurotrophic factor (BDNF), corticotropin releasing hormone receptor 1 (CRHR1) and FK506 binding protein 5 (FKBP5) as putative regulators of the antidepressant response. A high rate of failure of replication has also been reported. Pharmacogenetics will hopefully provide the basis for personalised antidepressant treatment that is able to maximise the probability of a good response and to minimise side effects; however, this goal is not achievable at the moment. The extent of the validity of the replicated findings and the reasons for the poor results obtained from studies of the pharmacogenetics of the antidepressant response are discussed.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Maier W, Zobel A. Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics. Eur Arch Psychiatry Clin Neurosci. 2008;258(Suppl 1):12–20. - PubMed
    1. Karasu TB, Gelenberg A, Merriam A, Wang P. American Psychiatric Association practice guideline for the treatment of patients with major depressive disorder. Am J Psychiatry. 2000;157:1–45. - PubMed
    1. Trivedi MH, Rush AJ, Wisniewski SR. et al.Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry. 2006;163:28–40. doi: 10.1176/appi.ajp.163.1.28. - DOI - PubMed
    1. Serretti A, Zanardi AR, Rossini D. et al.Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry. 2001;6:586–592. doi: 10.1038/sj.mp.4000876. - DOI - PubMed
    1. Dempfle A, Scherag A, Hein R. et al.Gene-environment interactions for complex traits: Definitions, methodological requirements and challenges. Eur J Hum Genet. 2008;16:1164–1172. doi: 10.1038/ejhg.2008.106. - DOI - PubMed

Substances